Literature DB >> 10101037

Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies.

N J Birdsall1, T Farries, P Gharagozloo, S Kobayashi, S Lazareno, M Sugimoto.   

Abstract

In radioligand binding studies, it has been reported that brucine, N-chloromethyl brucine, and brucine N-oxide increased the affinity of acetylcholine for M1, M3, and M4 muscarinic receptors, respectively, in a manner consistent with the predictions of the ternary complex allosteric model. We now demonstrate an equivalent ability of these three allosteric agents to modulate the actions of acetylcholine in functional studies in membranes and in whole cells. The enhancing actions of brucine and brucine N-oxide on acetylcholine (ACh) potency at M1 and M4 receptors respectively have been confirmed in guanosine-5'-O-(3-[35S]thio)triphosphate, GTPase, cAMP, and intracellular Ca2+ mobilization assays of function. In general, neither the basal nor the maximally stimulated response to ACh is affected. The subtype-selective allosteric effects of N-chloromethyl brucine on M2 and M3 receptors were shown to be qualitatively and quantitatively the same in guanosine-5'-O-(3-[35S]thio)triphosphate functional assays, in terms of both its affinity and cooperativity with ACh, as those found in binding assays. Neutral cooperativity of N-chloromethyl brucine with ACh on M4 receptor function was also observed, thereby demonstrating its "absolute subtype selectivity": a lack of action at any concentration at M4 receptors and an action at M2 and M3 receptors. The enhancing action of N-chloromethyl brucine on neurogenically released ACh binding at M3 receptors was also detected in whole tissue as an increased contraction of the isolated guinea pig ileum to submaximal electrical stimulation. In conclusion, these functional studies confirm that brucine analogs are allosteric enhancers of ACh affinity at certain muscarinic receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10101037

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  21 in total

Review 1.  Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.

Authors:  Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  The antipsychotic potential of muscarinic allosteric modulation.

Authors:  Thomas M Bridges; Evan P LeBois; Corey R Hopkins; Michael R Wood; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  Drug News Perspect       Date:  2010-05

Review 3.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

4.  DFT calculation of four new potential agents muscarinic of bispyridinium type: structure, synthesis, biological activity, hydration, and relations with the potents W84 and DUO-3O.

Authors:  M Alcolea Palafox; P Posada-Moreno; A L Villarino-Marín; C Martinez-Rincon; I Ortuño-Soriano; I Zaragoza-García
Journal:  J Comput Aided Mol Des       Date:  2010-12-22       Impact factor: 3.686

5.  Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists.

Authors:  L Michelle Lewis; Douglas Sheffler; Richard Williams; Thomas M Bridges; J Phillip Kennedy; J T Brogan; Matthew J Mulder; Lyndsey Williams; Natalia T Nalywajko; Colleen M Niswender; Charles D Weaver; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2008-01-04       Impact factor: 2.823

6.  Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity.

Authors:  Joy E Marlo; Colleen M Niswender; Emily L Days; Thomas M Bridges; Yun Xiang; Alice L Rodriguez; Jana K Shirey; Ashley E Brady; Tasha Nalywajko; Qingwei Luo; Cheryl A Austin; Michael Baxter Williams; Kwangho Kim; Richard Williams; Darren Orton; H Alex Brown; Craig W Lindsley; C David Weaver; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2008-12-01       Impact factor: 4.436

7.  Synthesis and SAR of N-(4-(4-alklylpiperazin-1-yl)phenyl)benzamides as muscarinic acetylcholine receptor subtype 1 (M1) anatgonists.

Authors:  Nicole R Miller; R Nathan Daniels; David Lee; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2010-02-13       Impact factor: 2.823

8.  Cooperative interactions at M2 muscarinic acetylcholine receptors: structure/activity relationships in stepwise shortened bispyridinium- and bis(ammonio)alkane-type allosteric modulators.

Authors:  Ralf Gilsbach; Maren Grossmüller; Vildan Alptüzün; Ercin Erciyas; Christian Tränkle; Ulrike Holzgrabe; Klaus Mohr
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

9.  Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

Authors:  W Y Chan; D L McKinzie; S Bose; S N Mitchell; J M Witkin; R C Thompson; A Christopoulos; S Lazareno; N J M Birdsall; F P Bymaster; C C Felder
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-04       Impact factor: 11.205

10.  Divergence of allosteric effects of rapacuronium on binding and function of muscarinic receptors.

Authors:  Jan Jakubík; Alena Randáková; Esam E El-Fakahany; Vladimír Dolezal
Journal:  BMC Pharmacol       Date:  2009-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.